Ulodesine
Ulodesine, also known as BCX4208, is a purine nucleoside phosphorylase (PNP) inhibitor in development as a once-daily oral, chronic treatment for gout. Ulodesine is currently being developed by Biocryst. Ulodesine acts upstream of xanthine oxidase in the purine metabolism pathway to reduce the production of serum uric acid (sUA). Ulodesine has an IC(50) of 0.5 nM to PNP. BCX-4208 is currently undergoing early clinical investigation in psoriasis and gout.
For research use only. We do not sell to patients.
Chemical Information
| Name | Ulodesine |
|---|---|
| Iupac Chemical Name | 7-(((3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one |
| Synonyms | BCX4208, BCX 4208, BCX-4208, Ulodesine, DADMe-immucillin H |
| Molecular Formula | C12H16N4O3 |
| Molecular Weight | 264.28 |
| Smile | O=C1C(NC=C2CN3C[C@H](O)[C@@H](CO)C3)=C2N=CN1 |
| InChiKey | AFNHHLILYQEHKK-BDAKNGLRSA-N |
| InChi | InChI=1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1 |
| CAS Number | 548486-59-5 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white solid |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Bantia S, Parker C, Upshaw R, Cunningham A, Kotian P, Kilpatrick JM, Morris P, Chand P, Babu YS. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Int Immunopharmacol. 2010 Jul;10(7):784-90. doi: 10.1016/j.intimp.2010.04.009. Epub 2010 Apr 22. PubMed PMID: 20399911.
2: Kamath VP, Juarez-Brambila JJ, Morris PE Jr. Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7. doi: 10.1002/dta.24. PubMed PMID: 20355185.
Chemical Structure
